Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EBT (2016 - 2025)

Historic EBT for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$65.2 million.

  • Ocular Therapeutix's EBT fell 3313.13% to -$65.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$263.5 million, marking a year-over-year decrease of 5962.16%. This contributed to the annual value of -$263.5 million for FY2025, which is 5962.16% down from last year.
  • Latest data reveals that Ocular Therapeutix reported EBT of -$65.2 million as of Q4 2025, which was down 3313.13% from -$68.0 million recorded in Q3 2025.
  • Ocular Therapeutix's EBT's 5-year high stood at -$19.5 million during Q1 2022, with a 5-year trough of -$68.0 million in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's median EBT value was -$22.9 million (recorded in 2022), while the average stood at -$34.4 million.
  • As far as peak fluctuations go, Ocular Therapeutix's EBT soared by 1094.77% in 2022, and later crashed by 11550.88% in 2024.
  • Ocular Therapeutix's EBT (Quarter) stood at -$19.7 million in 2021, then fell by 5.38% to -$20.8 million in 2022, then dropped by 9.42% to -$22.7 million in 2023, then crashed by 115.51% to -$49.0 million in 2024, then plummeted by 33.13% to -$65.2 million in 2025.
  • Its EBT was -$65.2 million in Q4 2025, compared to -$68.0 million in Q3 2025 and -$67.2 million in Q2 2025.